Genprex, Inc. (GNPX)
GNPX moved a median of -1.17% 30 minutes after news, and -2.33% by the close. How GNPX actually reacts to news — the realized, point-in-time move the market made, measured across 241 labeled events over the last three years with zero look-ahead.
GNPX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.34% | 41% | 234 |
| 30-min | -1.17% | 33% | 240 |
| 60-min | -1.35% | 34% | 241 |
| to close | -2.33% | 32% | 241 |
| Middle 50% of GNPX reactions | -3.84% to +1.29% |
|---|---|
| Median reaction (30-min) | -1.17% |
| Measured reactions | 241 |
Half of all Genprex, Inc. news events land between -3.84% and +1.29% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when GNPX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to GNPX's baseline. Nothing else.
Recent GNPX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Genprex to Present at the H.C. Wainwright 28th Annual Global Investment Conference | Press release | PR Newswire | +0.00% | +2.02% | |
| Form 8-K Genprex, Inc. For: Aug 18 | SEC filing · Form 8-K | SEC EDGAR | -4.95% | -6.84% | |
| Genprex Selects Leading Clinical and Commercial Contract Development and Manufacturing Organization for Manufacturing Scale Up of Diabetes Gene Therapy | Press release | PR Newswire | -4.95% | -6.84% | |
| Form 10-Q Genprex, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.41% | -12.20% | |
| Form 8-K Genprex, Inc. For: Aug 04 | SEC filing · Form 8-K | SEC EDGAR | -2.25% | -0.23% | |
| Form 8-K Genprex, Inc. For: Aug 03 | SEC filing · Form 8-K | SEC EDGAR | -2.18% | -5.75% | |
| Genprex Announces Collaboration with Roche Diagnostics for Biomarker Assay Validation Studies | Press release | PR Newswire | -2.18% | -5.75% | |
| Form 8-K Genprex, Inc. For: Jul 29 | SEC filing · Form 8-K | SEC EDGAR | +1.33% | -0.50% | |
| Form 8-K Genprex, Inc. For: Jul 13 | SEC filing · Form 8-K | SEC EDGAR | -2.65% | -9.81% | |
| Form S-8 Genprex, Inc. | SEC filing · Form S-8 | SEC EDGAR | -3.38% | -4.72% | |
| Form 8-K Genprex, Inc. For: Jun 22 | SEC filing · Form 8-K | SEC EDGAR | -4.26% | -7.08% | |
| Genprex Receives a Notice of Allowance from The Canadian Intellectual Property Office for a Patent Claiming the Combination of Reqorsa® Gene Therapy with Either PD-1 or PD-L1 Antibodies to Treat Cancer | Press release | PR Newswire | -4.26% | -7.08% | |
| Form 8-K Genprex, Inc. For: Jun 18 | SEC filing · Form 8-K | SEC EDGAR | -4.26% | -7.08% | |
| Genprex to Participate at BIO International Convention 2026 | Press release | PR Newswire | +4.61% | +14.28% | |
| Form 8-K Genprex, Inc. For: Jun 10 | SEC filing · Form 8-K | SEC EDGAR | +1.61% | -20.23% | |
| Form S-3 Genprex, Inc. | SEC filing · Form S-3 | SEC EDGAR | +1.94% | +3.10% | |
| Form 8-K Genprex, Inc. For: May 26 | SEC filing · Form 8-K | SEC EDGAR | +0.43% | -3.08% | |
| Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy Published at the 2026 ASCO Annual Meeting | Press release | PR Newswire | +0.43% | -3.08% | |
| Form 8-K Genprex, Inc. For: May 14 | SEC filing · Form 8-K | SEC EDGAR | -0.40% | +0.15% | |
| Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting | Press release | PR Newswire | -0.40% | +0.15% | |
| Form 10-Q Genprex, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -0.40% | +0.15% | |
| Form 8-K Genprex, Inc. For: Apr 30 | SEC filing · Form 8-K | SEC EDGAR | +1.67% | +8.33% | |
| Genprex Receives Patent Grant from The Israel Patent Office for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer | Press release | PR Newswire | +1.67% | +8.33% | |
| Form ARS Genprex, Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +1.67% | +8.33% | |
| Form DEF 14A Genprex, Inc. For: Jun 18 | SEC filing · Form DEF | SEC EDGAR | +1.67% | +8.33% | |
| Form 8-K Genprex, Inc. For: Apr 28 | SEC filing · Form 8-K | SEC EDGAR | -0.87% | -0.53% | |
| Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting | Press release | PR Newswire | -0.87% | -0.53% | |
| Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy To Be Released at the 2026 ASCO Annual Meeting | Press release | PR Newswire | -4.09% | -7.27% | |
| Form 8-K Genprex, Inc. For: Apr 21 | SEC filing · Form 8-K | SEC EDGAR | -8.71% | -17.42% | |
| Genprex Signs Sponsored Research Agreement to Study Biomarkers that May Predict Patient Response to Reqorsa® Gene Therapy | Press release | PR Newswire | -8.71% | -17.42% | |
| Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting | Press release | PR Newswire | -3.85% | -11.15% | |
| Form PRE 14A Genprex, Inc. For: Jun 18 | SEC filing · Form PRE | SEC EDGAR | -3.85% | -11.15% | |
| Form 10-K Genprex, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +2.31% | +4.62% | |
| Form 8-K Genprex, Inc. For: Mar 18 | SEC filing · Form 8-K | SEC EDGAR | -1.93% | -2.90% | |
| Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting | Press release | PR Newswire | -1.93% | -2.90% | |
| Genprex to Participate at BIO Europe Spring 2026 | Press release | PR Newswire | +0.00% | +0.00% | |
| Form 8-K Genprex, Inc. For: Feb 23 | SEC filing · Form 8-K | SEC EDGAR | -1.06% | +20.75% | |
| Genprex Strengthens Intellectual Property Portfolio with Japanese and EU Patents for Reqorsa® Gene Therapy in Combination with Immunotherapies to Treat Cancer | Press release | PR Newswire | -1.06% | +20.75% | |
| Form 8-K Genprex, Inc. For: Feb 10 | SEC filing · Form 8-K | SEC EDGAR | +0.54% | -0.46% | |
| Genprex Announces IP Australia's Intent to Grant Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers | Press release | PR Newswire | +0.54% | -0.46% | |
| Form 8-K Genprex, Inc. For: Jan 07 | SEC filing · Form 8-K | SEC EDGAR | -2.73% | +9.24% | |
| Form S-8 Genprex, Inc. | SEC filing · Form S-8 | SEC EDGAR | -2.73% | +9.24% | |
| Form 8-K Genprex, Inc. For: Jan 07 | SEC filing · Form 8-K | SEC EDGAR | -0.60% | -3.08% | |
| Genprex Provides Clinical Update on Diabetes Gene Therapy Program | Press release | PR Newswire | -0.60% | -3.08% | |
| Form 8-K Genprex, Inc. For: Jan 06 | SEC filing · Form 8-K | SEC EDGAR | -4.84% | +0.53% | |
| Genprex Announces Positive Preliminary Preclinical Data from Study of GPX-002 in Type 2 Diabetic Animal Studies | Press release | PR Newswire | -4.84% | +0.53% | |
| Form 8-K Genprex, Inc. For: Dec 23 | SEC filing · Form 8-K | SEC EDGAR | -0.50% | -5.50% | |
| Form EFFECT Genprex, Inc. | SEC filing · Form EFFECT | SEC EDGAR | +0.69% | -11.03% | |
| Form 8-K Genprex, Inc. For: Nov 25 | SEC filing · Form 8-K | SEC EDGAR | -0.34% | +0.00% | |
| Form S-1/A Genprex, Inc. | SEC filing · Form S-1 | SEC EDGAR | +2.06% | +1.72% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the GNPX section they belong to.
Where else GNPX is measured.
GNPX earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Adial Pharmaceuticals, Inc (ADIL) | 241 | 0.00% | 44% |
| Dare Bioscience, Inc. (DARE) | 241 | 0.00% | 43% |
| Allakos Inc. (ALLK) | 240 | -0.70% | 35% |
| AMN Healthcare Services Inc AMN Healthcare Services Inc (AMN) | 240 | -0.05% | 48% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Genprex, Inc.'s median reaction calculated?
Every labeled GNPX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 241 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 33% of GNPX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does GNPX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.